Health
UK government backs plan to ease licensing for psychedelic clinical trials
Synthesized from1 source
AI-generated summary
UK government backs plan to ease licensing for psychedelic clinical trials
The government has backed plans to streamline licensing for some psychedelic clinical trials, while a royal college report warned of dangers and researchers called for more evidence.
- The government has backed plans to ease licensing requirements for some psychedelic clinical trials, with a cross‑government working group coordinating the rollout.
- Since 2022, more than 20 clinical trials have tested psychedelic medicines for conditions including depression, PTSD, and addiction.
- The Royal College of Psychiatrists published a report in September 2025 warning of potential dangers of psychedelics.
- Prof Oliver Howes said psychedelic treatments should not be routine medical practice outside research settings until larger trials provide robust evidence for safety and effectiveness.
Coverage
1 outlet — read the original reporting
Every story is brought together from multiple sources into a single, clear summary — with every perspective kept, not flattened.